TOP > 外国特許検索 > PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS

PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS NEW

外国特許コード F180009470
整理番号 S2016-0625-C0
掲載日 2018年7月31日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP013525
国際公開番号 WO 2017191720
国際出願日 平成29年3月31日(2017.3.31)
国際公開日 平成29年11月9日(2017.11.9)
優先権データ
  • 特願2016-093483 (2016.5.6) JP
発明の名称 (英語) PREDICTION OF HEPATOCELLULAR CARCINOMA ONSET AFTER CLEARANCE OF HEPATITIS C VIRUS NEW
発明の概要(英語) The present invention addresses the problem of providing a predictive marker useful for carcinogenesis surveillance after hepatitis C viral clearance. Provided is a predictive marker comprising a single-nucleotide polymorphism specified by rs17047200. In the present invention, the abovementioned single-nucleotide polymorphism is detected in a nucleic acid specimen collected from a subject, and the risk of hepatocellular carcinoma onset after hepatitis C viral clearance is examined.
特許請求の範囲(英語) [claim1]
1. Taken from a subject nucleic acid in the sample, National Center for Biotechnology Information (NCBI) of the numbers in the registered database SNP rs17047200 single nucleotide polymorphisms identified in said detecting, after as well as viral clearance of hepatocellular carcinoma in hepatitis C at risk of developing inspection method.
[claim2]
2. (A) less than or equal to - (c) determining the risk in accordance with the criteria of any one of claims characterized in that, the inspection method according to claim 1 risk: allyl T (a) the base is detected to have a high risk;<AT type AA (b) the risk of the risk, the risk type TT;<AT type AA (c) risk of the risk of the risk type<TT.
[claim3]
3. Wherein the single nucleotide polymorphisms, elderly, male, platelet low value, liver fibrosis progression, molles ALT, afetoprotein LErafAON α -, γ-GTP molles, albumin low value, selected from the group consisting of diabetes and combined by at least one combination of risk factors, determine risk of developing hepatocellular carcinoma characterized in that, the inspection method according to claim 1 or 2 risk.
[claim4]
4. (Ii) the following step (i) and a determination procedure, the risk that an inspection method according to claim 3, liver fibrosis subject (i) a classification of the stage, and (ii) said single nucleotide polymorphism, elderly, male, platelet low value, molles ALT, afetoprotein LErafAON α -, γ-GTP molles, albumin low value, diabetes and complications are selected from the group consisting of a combination of one or more risk factors and further classifying the subject, the step of determining the risk of the subject.
[claim5]
5. (I) in the step of, hepatic fibrosis 1 of the first section and the 0-2 stage, the first stage of liver fibrosis 3-4 2 sections are set, the subject 1 is classified into the first case, and the single-nucleotide polymorphisms wherein, as the combination of the risk factors for the elderly further classifies the subject, the subject to determine the risk of, in which the subject has been classified into the first case 2, and the single-nucleotide polymorphisms wherein, as a risk factor of low value and to set the maximum afetoprotein α - albumin in combination with a further subject classification, determining the risk of a subject, the risk that an inspection method according to claim 4.
[claim6]
6. (I) comprising the following steps, according to any one of claims 1-5 risk of inspection method, (I) based on the determination result, determining a course of treatment of a subject step or change.
[claim7]
7. A database of the National Center for Biotechnology Information (NCBI) numbers in the registered SNP rs17047200 single nucleotide polymorphisms identified in the nucleic acid of for detecting, in a predetermined area containing the polymorphic site wherein the complementary sequences, wherein the region capable of specifically hybridizing to a nucleic acid, as well as viral clearance of hepatitis C after reagent for inspection is at risk of developing hepatocellular carcinoma.
[claim8]
8. A reagent according to claim 7, hepatitis virus C after eliminating the risk of developing hepatocellular carcinoma of the kit.
[claim9]
9. A database of the National Center for Biotechnology Information (NCBI) numbers in the registered SNP rs17047200 consisting of single nucleotide polymorphisms identified, as well as viral clearance hepatitis C after onset of hepatocellular carcinoma in predictive marker.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA CITY UNIVERSITY
  • 発明者(英語)
  • TANAKA YASUHITO
  • MATSUURA KENTARO
国際特許分類(IPC)
指定国 (WO2017191720)
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close